Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine

Machado, J. Soares; Beykan, Seval; Herrmann, Ken; Laßmann, Michael

doi:10.1007/s00259-015-3289-x

Cited by 11 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2014, an effort to harmonize the EANM dosage card and the NACG resulted in new published versions of each [ 7 ]. In 2016, the EANM dosage card was amended for 68 Ga-labelled compounds, based on a publication by Machado et al [ 8 ]. The NACG were also amended around this same time [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of modern PET technology and techniques on the EANM paediatric dosage card

Dickson

Eberlein

Laßmann

2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Aim Recent advancements in PET technology have brought with it significant improvements in PET performance and image quality. In particular, the extension of the axial field of view of PET systems, and the introduction of semiconductor technology into the PET detector, initially for PET/MR, and more recently available long-field-of-view PET/CT systems (≥ 25 cm) have brought a step change improvement in the sensitivity of PET scanners. Given the requirement to limit paediatric doses, this increase in sensitivity is extremely welcome for the imaging of children and young people. This is even more relevant with PET/MR, where the lack of CT exposures brings further dose reduction benefits to this population. In this short article, we give some details around the benefits around new PET technology including PET/MR and its implications on the EANM paediatric dosage card. Material and methods Reflecting on EANM adult guidance on injected activities, and making reference to bed overlap and the concept of MBq.min bed−1 kg−1, we use published data on image quality from PET/MR systems to update the paediatric dosage card for PET/MR and extended axial field of view (≥ 25 cm) PET/CT systems. However, this communication does not cover the expansion of paediatric dosing for the half-body and total-body scanners that have recently come to market. Results In analogy to the existing EANM dosage card, new parameters for the EANM paediatric dosage card were developed (class B, baseline value: 10.7 MBq, minimum recommended activity 10 MBq). The recommended administered activities for the systems considered in this communication range from 11 MBq [18F]FDG for a child with a weight of 3 kg to 149 MBq [18F]FDG for a paediatric patient weight of 68 kg, assuming a scan of 3 min per bed position. The mean effective dose over all ages (1 year and older) is 2.85 mSv. Conclusion With this, recommendations for paediatric dosing are given for systems that have not been considered previously.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In order to be consistent with the previous versions of the EANM dosage card and the methodology described [ 4 , 5 , 7 , 8 ], the following reduced values for [ 18 F]FDG PET/MR and long-field-of-view PET/CT are proposed for a scan duration of 3 min per bed position:…”

Section: Introductionmentioning

confidence: 99%

The effect of modern PET technology and techniques on the EANM paediatric dosage card

Dickson

Eberlein

Laßmann

2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…68 Ga is derived from generators and, therefore, more easily available and practical for centers that do not have cyclotrons. Its short half-life (68 min) allows for 1-day imaging and results in a lower radiation exposure than [ 123 I]-and [ 18 F]-labeled tracers [18,91].…”

Section: Advantages and Limitationsmentioning

confidence: 99%

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments

Samim

Tytgat

Bleeker³

et al. 2021

JPM

View full text Add to dashboard Cite

Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, nuclear medicine has been essential for the staging and response assessment of neuroblastoma. Currently, the standard nuclear imaging technique is meta-[123I]iodobenzylguanidine ([123I]mIBG) whole-body scintigraphy, usually combined with single-photon emission computed tomography with computed tomography (SPECT-CT). Nevertheless, 10% of neuroblastomas are mIBG non-avid and [123I]mIBG imaging has relatively low spatial resolution, resulting in limited sensitivity for smaller lesions. More accurate methods to assess full disease extent are needed in order to optimize treatment strategies. Advances in nuclear medicine have led to the introduction of radiotracers compatible for positron emission tomography (PET) imaging in neuroblastoma, such as [124I]mIBG, [18F]mFBG, [18F]FDG, [68Ga]Ga-DOTA peptides, [18F]F-DOPA, and [11C]mHED. PET has multiple advantages over SPECT, including a superior resolution and whole-body tomographic range. This article reviews the use, characteristics, diagnostic accuracy, advantages, and limitations of current and new tracers for nuclear medicine imaging in neuroblastoma.

show abstract

“…Emphasis was placed on dose reduction techniques, particularly on the fact that the instrumental technologic developments can be used to reduce patient radiation dose. With the development and progressive implementation of PET/MR scanners, a significant reduction of 18 F-FDG activity can be achieved (4), and it is strongly encouraged that retrospective-dosimetry and image-quality studies be performed with emerging radiopharmaceuticals and radionuclides (5).…”

Section: Dose Reduction Principlesmentioning

confidence: 99%

Technologist Approach to Global Dose Optimization

Costa

Testanera

Camoni

et al. 2018

J. Nucl. Med. Technol.

View full text Add to dashboard Cite

show abstract

Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine

Abstract: For paediatric nuclear medicine applications involving (68)Ga-labelled peptides, we suggest determining administered activities based on the formalism proposed in this work. The corresponding effective doses from these procedures will remain age-independent.

Cited by 11 publications

References 12 publications

The effect of modern PET technology and techniques on the EANM paediatric dosage card

The effect of modern PET technology and techniques on the EANM paediatric dosage card

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments

Technologist Approach to Global Dose Optimization

Contact Info

Product

Resources

About